Additionally, venetoclax enhances the activity of bortezomib in MM cell lines and NCI H929 xenograft models, pointing toward an additive effect exerted by BCL2 inhibition and MCL-1 blocking by binding the BCL2-family member NOXA in a bortezomib-dependent fashion [126,127]. This evidence concerns the gene BCL2 and Miyoshi myopathy.